Journal article
Immunodominant CD4 responses identified in a patient vaccinated with full-length NY-ESO-1 formulated with ISCOMATRIX adjuvant
Q Chen, H Jackson, P Parente, T Luke, M Rizkalla, TY Tai, HC Zhu, NA Mifsud, N Dimopoulos, KA Masterman, W Hopkins, H Goldie, E Maraskovsky, S Green, L Miloradovic, J McCluskey, LJ Old, ID Davis, J Cebon, W Chen
Proceedings of the National Academy of Sciences of the United States of America | NATL ACAD SCIENCES | Published : 2004
Abstract
There is increasing evidence showing the involvement of CD4+ T cells in initiating and maintaining antitumor immune responses. NY-ESO-1 is expressed by various tumors but not normal tissues except testis. We conducted a cancer clinical trial by using full-length NY-ESO-1 protein formulated with ISCOMATRIX adjuvant and injected into patients intramuscularly. Autologous dendritic cells pulsed with NY-ESO-1 ISCOMATRIX in combination with overlapping synthetic peptides were used to identify immunodominant T cells from a vaccinated patient. We show here the identification and characterization of two novel CD4+ T cell epitopes. T cells specific to these epitopes not only recognized autologous dend..
View full abstract